Sickle Cell Disease
ICER will assess the comparative clinical effectiveness and value of crizanlizumab (Novartis) and voxelotor (Global Blood Therapeutics) for the treatment of sickle cell disease. Crizanlizumab, a P-selectin inhibitor, is currently under FDA priority review with an anticipated decision expected in the first half of 2020. Global Blood Therapeutics is planning to initiate and complete a rolling NDA for voxelotor, an HbS polymerization inhibitor, before the end of 2019.
For questions, please contact Catherine Koola, Program Manager, at email@example.com.
The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for sickle cell disease.